Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06262789

RAT-HEMATO : Return to Work After Malignant Hemopathy

Return to work (RTW) of patients after cancer treatment has been a topic of growing interest for the past two decades. Advances in cancer care have led to better patient survival, with some cancers considered as chronic or even cured diseases. The return of patients to their "pre-cancer life" can thus become an objective. Indeed, RTW after cancer is associated with improved quality of life for patients in several studies (improved financial status, improved social contacts, return of functional abilities and improved self-esteem). However, many difficulties can interfere with RTW. Many factors have been identified: disease, treatment, patient and occupational factors. The feeling of "return-to-work self-efficacy" is one of the main psychological determinants and its interest has been recently demonstrated in oncology. It corresponds to a cognitive mechanism based on expectations and/or beliefs of an individual about being able to carry out the actions required to achieve a goal, in this case RTW. The majority of studies on RTW concerns solid cancer and are retrospective. Very few studies have focused on hematological malignancies, whose prognosis was, until recently, worse. Moreover, very few interventional studies exist. There is therefore a significant need for prospective studies with appropriate methodological tools to reliably assess the benefit of interventional measures on RTW. The investigators propose to conduct a prospective, comparative, randomized, multicenter study evaluating the impact of an early RTW-consultation in patients who have been treated for a hematological malignancy. The investigators hypothesize that this consultation will improve patients' RTW rates and RTW quality.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Leukemia Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Angers University hospital, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with hematological malignancy controlled after treatment
  • Induction/consolidation chemotherapy completed (excluding maintenance therapy)
  • Patient aged 18 to 55
  • Patient having worked at least 6 months in the 2 years before diagnosis of hematological malignancy
  • Patient who has not yet returned to work since diagnosis of hematological malignancy
  • Signed informed consent form

Exclusion criteria

  • Patient choosing not to return to work
  • Patient not affiliated to a social security system
  • Patient with legal guardian or legal trustee
  • Patient not understanding French
  • Patient with severe cognitive impairment at diagnosis, incompatible with the study

Treatment and study plan

"Return-to-work after cancer" consultation

Other

The "return-to-work after cancer" consultation is carried out by a specialist in occupational pathology, who may be assisted by a psychologist and/or a nurse and/or a social worker, depending on the patient's personal situation. During this consultation, the team assesses the patient's medical situation, social situation and psychological situation. This consultation lasts approximatively 1 hour and aims to guide the patient in the different stages of return to work, to identify obstacles and apprehensions about return to work, to assess the patient's functional capacities and motivations, to provide information on the legislation, actors and tools for employment maintenance and to discuss possible adjustments of the work situation. The consultation provides a response to potential or encountered problems, directs the patient towards the actors and tools adapted to his/her situation.

Primary outcomes

  1. Return-to-work rate at 1 year (percentage)

    Time frame: 12 months

    The return-to-work rate at 1 year is used to assess the impact of an early "Return-to-work" after cancer consultation for patients with hematological malignancies. It is defined as the percentage of patients having returned to work, including part-time work, 1 year after the inclusion visit.

Secondary outcomes

  1. Cumulative incidence of return-to-work at 1 year

    Time frame: 12 months

    It is measured by the cumulative incidence rate of return-to-work at 1 year

  2. Change or not of the professional situation in the 2 arms

    Time frame: 12 months

    It is defined as the rate of patients with a change of their professional situation since the diagnosis. The changes of professional situation include: employment yes/no, full-time/part-time work, adaptation of work station yes/non, change of profession compared to before diagnosis.

  3. Factors influencing return to work

    Time frame: 12 months

    The factors investigated are type of hematological malignancy, sex, type of profession, presence of anxio-depressive disorders

  4. Quality of life (SF-12 score) evolution

    Time frame: Baseline, 3 months, 6 months and 12 months

    The 12-Item Short Form Survey (SF-12) is one of the most widely used tools in oncology to assess health-related quality of life. It is a general health questionnaire that measures physical and mental health. It consists of 12 questions split into 8 different dimensions: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Results are expressed in terms of two meta-scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). PCS and MCS scores range from 0 to 100, with higher scores indicating better physical and mental health functioning, respectively.

    We will evaluate SF-12 evolution between Baseline visit and each other visits.

  5. Anxiety and depression (HAD scale) evolution

    Time frame: Baseline , 3 months, 6 months and 12 months

    Hospital Anxiety and Depression Scale (HAD scale) is one the most widely tools used in oncology to assess patient anxiety and depression. It consists of 14 questions rated form 0 to 3: 7 questions relate to anxiety (total A) and 7 to depression (total D), giving two scores (maximum score for each = 21). Scores between 0 et 7 correspond to an absence of anxiety or depression, scores between 8 and 10 are considered as doubtful, and scores 11 and above correspond to depression or anxiety.

    We will evaluate HAD scale evolution between Baseline visit and each other visits.

  6. Return-to-work self-efficacy (RTW-SE-11 scale) evolution

    Time frame: Baseline, 3 months, 6 months and 12 months

    The Return-to-Work Self-Efficacy Scale - 11 items (RTW-SE-11) is an 11-item questionnaire measuring an individual's confidence in his or her ability to return to work. It integrates beliefs in the patient's abilities to support the physical, cognitive, emotional, relational and professional aspects of the work environment that have been identified as strong predictors of RTW following a cancer diagnosis. The final score ranges between 1 and 6, with a higher score indicating higher self-efficacy.

    We will evaluate RTW-SE-11 scale evolution between Baseline visit and each other visits.

  7. Self-assessment of the benefit of the "return-to-work after cancer" consultation

    Time frame: 3 months and 6 months

    Patients assess the benefit of the "return-to-work after cancer" consultation using a questionnaire specially designed for the study, composed of Likert-scale questions. For each question, score ranges from 1 to 5. Higher scores indicate higher satisfaction.

    We will evaluate RTW-SE-11 scale evolution between 3 months visit and 6 months visit (only for patients randomized in intervention arm).

Study contacts

Contact information is provided by the study sponsor or research team.

Aline SCHMIDT, MD

CONTACT

[email protected]

02 41 35 44 82 ext. + 33

Jérome PAILLASSA, MD

CONTACT

[email protected]

02 41 35 44 72 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Angers

Other Gov

Registry information

Acronym: RAT-HEMATO

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Feb 16, 2024
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.